NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.61 +0.59 (+0.76%) GOLD FUTURES
2,392.30 +32.40 (+1.37%) DOW
39,814.12 +256.01 (+0.65%) Bitcoin GBP
51,618.85 +3,279.40 (+6.78%)
MRK Jan 2025 135.000 put
| Previous close | 9.30 |
| Open | 9.00 |
| Bid | 8.85 |
| Ask | 9.05 |
| Strike | 135.00 |
| Expiry date | 2025-01-17 |
| Day's range | 9.00 - 9.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 386 |
Business WireMerck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
RAHWAY, N.J., May 15, 2024--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
ZacksMerck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
BenzingaMerck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Monday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab) compared to Keytruda alone as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV). Also Read: Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook. Data from a pre-planned analysis showed tha
